Publications by authors named "R Kaczmarski"
Background: Hyperhaemolysis is a rare and life-threatening delayed haemolytic transfusion reaction characterised by complement-mediated destruction of both host and transfused red cells. It is well recognised as a complication of transfusion in patients with haemoglobinopathies and has occasionally been described in haematological malignancy and anaemia of chronic disease. Anti-HI antibodies are usually clinically insignificant but have rarely been associated with haemolytic transfusion reactions, including cases of hyperhaemolysis in sickle cell disease.
View Article and Find Full Text PDFArticle Synopsis
- Aberrant NF-κB activity is linked to the development and survival of multiple myeloma (MM) and various other cancers, yet no specific inhibitors have been approved clinically due to harmful side effects from existing drugs.
- Researchers have developed a new inhibitor called DTP3, which selectively targets a cancer-specific survival mechanism related to NF-κB, effectively killing MM cells without harming healthy ones.
- Preclinical studies show that DTP3 has favorable properties, including effectiveness against cancer, a long-lasting presence in the body, and no toxic effects, leading to its approval for clinical trials in cancer treatment.
Purpose: To identify factors that determine patients' intentions to use point-of-care medical devices, ie, portable coagulometer devices for self-testing of the international normalized ratio (INR) required for ongoing monitoring of blood-coagulation intensity among patients on long-term oral anticoagulation therapy with vitamin K antagonists, eg, warfarin.
Methods: A cross-sectional study that applied the technology-acceptance model through a self-completed questionnaire, which was administered to a convenience sample of 125 outpatients attending outpatient anticoagulation services at a district general hospital in London, UK. Data were analyzed using descriptive statistics, factor analyses, and structural equation modeling.